Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases
Article first published online: 1 MAR 2012
© 2012 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1253, Glycobiology of the Immune Response pages 159–169, April 2012
How to Cite
Angata, T., Fujinawa, R., Kurimoto, A., Nakajima, K., Kato, M., Takamatsu, S., Korekane, H., Gao, C.-X., Ohtsubo, K., Kitazume, S. and Taniguchi, N. (2012), Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Annals of the New York Academy of Sciences, 1253: 159–169. doi: 10.1111/j.1749-6632.2012.06469.x
- Issue published online: 23 APR 2012
- Article first published online: 1 MAR 2012
- chronic inflammation;
- Alzheimer’s disease;
- chronic obstructive pulmonary disease;
- systems biology
Glycobiology has contributed tremendously to the discovery and characterization of cancer-related biomarkers containing glycans (i.e., glyco-biomarkers) and a more detailed understanding of cancer biology. It is now recognized that most chronic diseases involve some elements of chronic inflammation; these include cancer, Alzheimer's disease, and metabolic syndrome (including consequential diabetes mellitus and cardiovascular diseases). By extending the knowledge and experience of the glycobiology community regarding cancer biomarker discovery, we should be able to contribute to the discovery of diagnostic/prognostic glyco-biomarkers of other chronic diseases that involve chronic inflammation. Future integration of large-scale “omics”-type data (e.g., genomics, epigenomics, transcriptomics, proteomics, and glycomics) with computational model building, or a systems glycobiology approach, will facilitate such efforts.